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ABSTRACT
Cardiovascular complications are the leading cause of diabetes-related morbidity
and mortality. Calpain, a calcium-dependent protease, is increased in diabetic hearts yet
its role in diabetic heart disease has not been demonstrated. We hypothesized that
inhibition of calpain activity via calpastatin (CAST) over-expression will reduce the
onset of myocardial fibrosis, a hallmark of diabetic cardiomyopathy, in the Type 2
murine model, db/db. Histological analysis together with gene expression measurements
showed calpastatin over-expression reduced collagen content in db/db-CAST hearts. In
order to understand the mechanisms responsible for this change, fibroblasts and known
mediators of collagen synthesis and degradation were studied. Results indicated that
calpain-induced derangements in MMP activity, stimulation of immune cells and upregulation of cytokines responsible for promoting fibroblast differentiation and
proliferation were reversed by calpastatin over-expression. This study shows that calpain
inhibition is an effective means of decreasing collagen accumulation in the diabetic heart.

Keywords: diabetic cardiomyopathy; myocardial fibrosis; collagen; calpain; calpastatin;
calpastatin over-expression, fibroblasts; db/db
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CHAPTER 1: INTRODUCTION
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Section 1.1: Diabetes Mellitus and its Associated Complications
Diabetes is a chronic, metabolic disorder; the body cannot produce insulin to
regulate glucose or fails to use insulin adequately [1]. The result is elevated blood
glucose levels which impair physiological functions and lead to damaged organs, nerves
and vessels [1]. There are three main types o f diabetes including gestational diabetes
which occurs early in pregnancy but subsides after delivery [1-4],
Type 1 diabetes is an autoimmune disorder [1-4]. The body’s own T-cells attack
the (3-cells for unknown reason thus destroying pancreatic endocrine function and causing
absolute insulin deficiency [5]. Type 1 diabetes affects nearly 10% of the diabetic
population and is usually diagnosed in children and young adults [2-4],
Type 2 diabetes is of multifactorial etiology. It is caused by the combined
influence of genetic susceptibility and environmental variables such as age, weight, diet
and physical inactivity [1,4-5]. Insulin production may not be sufficient to meet the
body’s needs. Alternatively, insulin-resistance can develop where the pancreas continues
to produce insulin but the body no longer responds to its action [5].
Diabetes is a global pandemic; by 2030, nearly 400 million people will have been
diagnosed with it [3]. In Canada alone, 1.2 million people are expected to be diagnosed
between 2010 and 2020, bringing the total to 3.7 million [2]. Coping with diabetes is a
tremendous struggle in itself. Nonetheless, it can introduce a number of complications
including visual impairments and blindness, nerve and kidney damage [1-4]. However,
the greatest challenges lie in cardiovascular complications, now the leading cause of
diabetes-related morbidity and mortality [3-4], In Canada, 80% of diabetics die from a
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heart attack or a stroke [2]. In 2004 in the United States, heart disease was noted on 68%
of diabetes-related death certificates among people aged 65 years or older [1].

Section 1.2: Cardiovascular complications and glycaemic control
Hyperglycaemia may be a risk factor for the development and progression of
cardiovascular disease similar to total cholesterol and blood pressure [6].
Epidemiological studies have long indicated a clear connection between the level of
hyperglycaemia and the occurrence of cardiovascular disease [7-11]. Surprisingly,
glycaemia does not need to rise to diabetic levels to increase the risk of cardiovascular
complications as even slight, sustained elevations in blood sugar are sufficient [8, 9, 11,

12].
In the Framingham Study, diabetic men had more than twice the frequency of
heart failure than their non-diabetic counterparts [7, 9,13-15]. Diabetic women are also
five times more susceptible to heart failure [7, 9, 13-15]. Additionally, diabetes can also
have a detrimental effect on the outcome of cardiovascular disease. Studies suggest that
following myocardial infarction, diabetic hearts are more likely to fail through future
cardiac events [7].
Clinical trials such as the Diabetes Control and Complications Trial (DCCT) and
the United Kingdom Prospective Diabetes Study (UKPDS) involving patients with Types
1 and 2 diabetes, respectively, have conclusively shown reductions in the risks of
diabetes complications after intensive diabetes therapy (IDT) [6, 8, 16]. Unlike
conventional therapy which aims only to prevent the symptoms of hyperglycaemia and
hypoglycaemia, IDT involved a more stringent regimen of insulin treatment [16].
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Intensive control of blood glucose reduced the risk of cardiovascular events by 42% and
severe clinical events, defined as non-fatal myocardial infarction, stroke and death from
cardiovascular disease by 57% in the DCCT [8, 16]. The UKPDS similarly demonstrated
the risk-reducing benefits of glycaemic control in the micro vasculature [11].

Section 1.3: Diabetic Cardiomyopathy
Decades ago. Rubier documented the existence of myocardial disease of unknown
cause in four diabetic patients [20]. Since then, numerous studies, both epidemiological
and clinical, have suggested the existence of a cardiomyopathy distinct to diabetics which
is not caused by pre-existing heart conditions such as hypertension or coronary artery
disease (CAD) [9, 17, 19, 21-23] and results from numerous alterations both structural
and metabolic (Figure 1.1).

Section 1.3.1: Metabolic changes in diabetic cardiomyopathy
Hyperglycaemia can introduce a number of adverse alterations in metabolism,
particularly substrate utilization, which could be an underlying mechanism leading to
cardiomyopathy [24-26]. Although the normal heart is able to derive energy from
multiple substrates including ketones, amino acids, carbohydrates and fatty acids,
approximately 70% of ATP generation occurs via fatty acid oxidation and the remaining
30% is provided by glucose and lactate [24, 27, 28], The diabetic myocardium however,
uses fatty acid oxidation almost exclusively for energy production [29].
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Figure 1.1: Schematic diagram illustrating some of the known mechanisms
underlying diabetic cardiomyopathy
Hyperglycaemia can induce a number of changes in the myocardium. Derangements in
cardiac metabolism lead to fatty acids becoming the dominant substrate for oxidation.
Once the supply o f free fatty acids exceeds the demand, lipotoxicity can occur. Fatty acid
oxidation can also introduce mitochondrial dysfunction and promote oxidative stress. The
coronary arteries are subject to accelerated atherosclerosis and the small vessels undergo
microangiopathy. Lastly, owing to hypertrophy and fibrosis, the architecture of the
myocardium changes. Diastolic dysfunction, with or without systolic dysfunction, is the
end result.
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Section 1.3.2: Fatty acid oxidation in the diabetic heart
Fatty acids play a vital role in maintaining the healthy cardiac myocyte and their
intracellular levels are tightly regulated [30]. Fatty acids are used as fuels, ligands for
nuclear transcription factors, mediators of intracellular signal transduction and they are
essential components of biological membranes [28]. Abnormalities in fatty acid
regulation can result in a number of pathologies not limited to cardiotoxicity. Under
diabetic conditions, increased lipolysis in adipose tissue combined with lipoprotein
synthesis in the liver releases substantially more free fatty acids into the circulation [31].
The heart adjusts to these new hyperlipidémie conditions by enhancing the expression of
fatty acid metabolizing proteins thus promoting fatty acid utilization [30], In this manner,
the cardiac muscle is initially able to compensate for the change in substrate availability
however, sustained exposure to this environment can lead to dysfunction [32, 33],
Moreover, if fatty acid supply exceeds the rate of their oxidation the subsequent
accumulation of lipids leads to lipotoxicity in the heart [31, 34].

Section 1.3.3: PPAR-a activation

In the mammalian heart, the expression of proteins for fatty acid oxidation is
increased in response to elevations of fatty acids. Gene expression is propagated by
peroxisome proliferator-activated receptor (PPAR)-alpha [35, 36], PPAR-a regulated
genes are involved in various steps of fatty acid metabolism. The increased expression of
fatty acid metabolizing genes coupled with the increase in fatty acid availability is largely
responsible for increased utilization of this substrate for energy [37-39]. PPAR-a
activation causes decreased expression of genes involved in glucose uptake, glycolysis,
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and pyruvate oxidation [24, 40], Additionally, glucose uptake is dependent on insulin but
impaired insulin functioning combined with reduced glucose transporter type 4 (GLUT4)
proteins limit glucose availability in cardiomyocytes [41, 42]. In contrast fatty acids can
enter the cardiac cells with ease, as they require no hormones. All these factors serve to
further promote the complete dependence o f the heart tissue on fatty acids.

Section 1.3.4: Functional and Structural Changes in Diabetic Cardiomyopathy
Cardiac complications typically involve the left ventricle, coronary arteries and
the microvasculature [43]. Studies of biopsy specimens reveal morphological changes at
the tissue level, chiefly myocyte hypertrophy and perivascular fibrosis. As such,
hypertrophy and fibrosis are hallmarks of diabetic cardiomyopathy [44]. Hypertrophy is
characterized by increased left ventricular mass, increased wall thickness, stiffness and
reduced chamber size [45-47], Myocardial fibrosis can further lead to ventricular wall
stiffness, reduced compliance, and impaired diastolic function thereby exacerbating
cardiac injury [48]. Diabetes can also accelerate atherosclerosis leading to coronary and
cerebral artery disease [15, 51, 52]. Systemic hyperglycaemia can damage small blood
vessels and cause a thickening of the basement membrane (BM) and eventual rupture
leading to reduced blood flow and leakage of proteins [53, 54], Although, many
mechanisms of hyperglycaemia-induced cardiac damage have been proposed, including
derangement in metabolism, the exact one(s) have not been clearly isolated [55].

Section 1.4: Fibrosis in the diabetic myocardium
In the heart, myocytes are surrounded by the cardiac extracellular matrix (ECM)
which is primarily composed of collagen with smaller amounts of elastin, laminin and
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proteoglycans among others [56, 57]. The dominant collagens are type I, accounting
anywhere from 50-80%, and type III collagen, comprising around 10% of the ECM; the
other collagens are present but to a much lesser degree [56, 57]. Collagen may also be
involved in the transmission of force generated by cardiac muscle [58]. Characterized by
excess collagen accumulation, myocardial fibrosis is believed to be a maladaptive
response occurring independently of organ hypertrophy [48]. Although studies indicate
that only 2-4% o f the myocardium is collagen, even slight changes in collagen
concentration can have substantial effects on the mechanical properties of the heart [56,
57, 59, 60].
Increased ventricular stiffness resulting from elevated levels of collagens can
inhibit myocyte recoil during cardiac relaxation resulting in aberrant ventricular filling
and consequently stroke volume [61, 62], Increases in collagen content impair sarcomere
extension and compromise the ability of the heart to generate adequate pressure for
systemic perfusion [61, 62]. With these factors taken together, it is clear that fibrosis
greatly jeopardizes myocardial function and not surprisingly, fibrosis is a leading cause
of heart failure (Figure 1.2) [56, 57, 59],
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Figure 1.2 Functional consequences of myocardial fibrosis
Fibrosis is a typical feature of diabetic cardiomyopathy. Collagen levels are elevated in
the diabetic heart and this starts a cascade event that culminates in cardiac dysfunction
that could lead to heart failure. The stiffness and non-compliance of the heart hampers its
mechanical abilities by limiting ventricular filling and preventing the complete extension
of the sarcomeres. The left ventricle consequently struggles to generate the adequate level
of pressure required for systemic perfusion.
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Section 1.5: Fibroblast Cell Involvement
Fibrosis is believed to be mediated by fibroblasts [63-67]. The precise manner in
which hyperglycaemia stimulates increased collagen deposition by fibroblasts in cardiac
tissue is not clearly understood [68]. One possibility is that high glucose up-regulates
transforming growth factor (TGF)-pi expression leading to increased fibroblast
proliferation [58, 65, 69-71], TGF-pi is a known fibrogenic factor and key regulator of
inflammation and wound healing; it is released at wound sites where it recruits
neutrophils, monocytes and fibroblasts to initiate tissue repair [69, 72]. It also plays a
central role in the maintenance of the ECM and can induce the expression of ECM
proteins including collagen from fibroblasts [58, 65, 72]. TGF-pl has also been
demonstrated to induce differentiation of fibroblasts to myofibroblasts [58, 65, 72].
Fibroblasts are quiescent but they migrate and proliferate upon activation [72]. During
the reparative process, tissue needs to be contracted and as a result a subpopulation of the
fibroblasts will gain contractile properties that resemble those belonging to smooth
muscle cells and this modulation allows the cell, now called a myofibroblast, to secrete
greater amounts of collagen [69, 73, 74].

Section 1.6: Other mechanisms of fibrosis: MMPs and NF-kB
Maintenance and degradation of the extracellular matrix in the myocardium is
regulated by matrix metalloproteinases (MMPs) which are regulated in turn by their
inhibitors, tissue inhibitors of metalloproteinases (TIMPs) [75-80]. Modifications in the
activities of either MMPs or TIMPs have marked effects on the architecture of the ECM
in the myocardium. In the event of impaired MMP regulation an imbalance in collagen

11

synthesis versus collagen degradation leads to the accumulation of fibrillar collagen and
the appearance of myocardial fibrosis [75, 80].
Lastly, a transcription factor implicated in fibrosis is nuclear factor-icB (NF-kB)
[81-84], When inactive, NF-kB is complexed to its inhibitor, inhibitor-KB (IkB) and is
thus prevented from entering the nucleus [85, 86]. Activation of IkB kinase (IKK) by
extracellular signals initiates the degradation of IkB [85, 86]. Phosphorylation of two
serine residues of the IkB structure by IKK leads to ubiquitination and subsequent
digestion by the proteasome. NF- kB becomes free to translocate into the nucleus and
transcribe its associated genes [85-87]. Specifically, NF-kB is responsible for the
activation of pro-inflammatory cytokines some of which, such as tumour necrosis factoralpha (TNF- a), are elevated in the diabetic heart [81, 82, 85]. Pro-inflammatory
cytokines can subsequently induce expression of other cytokines such as TGF-(11.
Furthermore, the pro-fibrogenic effect of these cytokines may also include MMP
activation [79].

Section 1.7: A Closer Look at Calpain
Calpains are one of three cysteine proteases; caspases and cathepsins are the other
two. In response to calcium signaling, calpains direct cellular functioning by cleaving
select proteins [88]. Calpain can exist in any one of fifteen different isoforms however;
the two most well-characterized members o f the calpain family in mammals are p-calpain
(calpain-1) and m-calpain (calpain-2) [88, 89]. They differ only in calcium sensitivity and
are ubiquitously distributed but their exact physiological function remains unknown.
Calpain exists in the cytosol as an inactive enzyme and translocates to the membrane in
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9+
response to increases in cellular Ca levels [88-90]. Calpain activity is regulated by

calpastatin, an endogenous inhibitor capable of reversible binding of the calpain
molecules in the presence of calcium [90].

Section 1.7.1: Structure and Activation
Calpain-1 and calpain-2 are both heterodimers consisting of an 80 kDa catalytic
subunit and a regulatory 30 kDa subunit [88], Although the 30 kDa subunit, encoded by
the CAPN4 gene, is identical in both calpains, the catalytic subunit is encoded by
different genes: human chromosome 11 for calpain-1 and human chromosome 1 for
calpain-2 [88], Nonetheless, the subunits share 55-65% homology [88], Calpain
I

activation is triggered by a Ca

flux which causes inactive calpain to translocate to the

plasma membrane where activation occurs in the presence of Ca2+ and phospholipids
[89].
The crystal structure of calpain reveals four domains (I-IV) in the 80 kDa subunit.
Domain II is subdivided into domains Ha and lib which surround the substrate binding
cleft [88, 89], The 30 kDa subunit has an additional two domains (V-VI) [88, 89]. The
first o f a two-step mechanism of activation is the release of constraints imposed by
interactions between the four domains of the 80 kDa subunit [88]. Upon Ca binding to
domains IV, VI and III, domain I is released from VI and domain II is released from III
resulting in the dissociation of the 80kDa subunit from the 30kDa subunit, a pre-requisite
for the formation of the catalytic site in the second stage [88, 89]. In the inactive
conformation o f calpain, further domain interactions separate subdomains Ha from lib, a
structural constraint that prevents the formation of an active cleft site [88]. The binding of
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two additional Ca

ions in the second step, one to domain Ha and the other to domain

lib, induces a conformational rearrangement vital for the formation of a functional
catalytic site [88, 89].

Section 1.7.2: The Biological Role

Calpains constitute a highly conserved superfamily existing ubiquitously from
humans to microorganisms and exist in all vertebrate cells examined thus far, suggesting
a vital biological role [88]. Mammalian calpains sequenced to date have shown a high
degree of homology in their amino acid sequences and there is little indication of
alternative splicing in the expression of the calpain gene [88], By modulating the
biological activity of their substrates, calpains influence a number of calcium-regulated
cellular processes including signal transduction, cell cycle progression, apoptosis and
cytoskeletal remodeling [90, 91].
Calpain is also able to cleave pro-caspase 3, 7, 8, 9 into inactive fragments and as
such has been implicated in apoptosis [92], Calpain has attracted much attention due to
the recent discovery of correlations between calpain gene mutations and human diseases.
Deregulation of calpain has been implicated in a number of pathologies including
secondary degeneration resulting from acute cellular stress, neuronal degeneration,
Alzheimer’s disease, metastasis, muscular dystrophy, cataracts and diabetes [93-95].
Calpain inhibition has been found to be protective in ischaemia injury models as well
[96], A recent study demonstrated that cardiac over-expression of calpain-1 is sufficient
to cause heart failure in transgenic mice [93, 97]. Our lab recently showed that
hyperglycaemia-induced calpain-1 activation, mediated through an NADPH oxidase-
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dependent pathway, can lead to apoptosis through down-regulation of (Na, K)-ATPase
activity in cardiomyocytes and in vivo diabetic hearts [92]. Calpain inhibition via
calpastatin over-expression imparted an anti-apoptotic effect on cardiomyocytes.
Calpain knockout models have indicated important roles for calpain-4, the
regulatory subunit, and also suggest m-calpain may be more important than p.-calpain for
embryonic development [98]. Compared to capn4+/' mice which had normal viability and
calpain activity, the capn4'Aembryos, generated by disrupting expression of the 80kDa
small subunit encoded by the calpain-4 gene (CAPN4), died by 11.5 days of gestation
after exhibiting cardiovascular abnormalities at day 10.5 [98], These embryos also had no
detectable calpain activity. Interestingly, in the embryonic stem cells, the RNA levels of
the 80kDa subunit of both calpains were normal however, the corresponding polypeptides
for each were nearly undetectable [98]. The results point to a role for the regulatory
subunit critical to cell survival that is currently unknown.
Transgenic capn 1 mice had significant decreases in platelet aggregation. It
appears that the presence of m-calpain can compensate for the lack of p-calpain and that
m-calpain and p-calpain may have the same substrates [88]. Previous studies have
established a physiological role for calpain in the degradation of polypeptides during
platelet activation however in the calpain-1 knockout mice these same polypeptides had
normal degradation patterns [96, 99, 100].
On the other hand, knockout of m-calpain has shown to be embryonically lethal
[88], This observation raises a few issues. First that m-calpain, along with calpain-4, must
play an essential role in embryonic development, perhaps certain cleavages, that calpain1 does not. Alternatively, a lack of embryonic lethality after calpain-1 knockout may be
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due to the relatively late expression o f p-calpain during development meaning, it would
not be involved in calpain-dependent cleavages required for continued growth thus
assigning it a non-essential function in embryonic development [88].

Section 1.7.3: Endogenous Regulation of Calpain Activity

Deregulation of calpain can lead to cellular damage and subsequent pathology
[95, 99, 101]. Calpain activity is thus tightly regulated by calcium availability as well as
an endogenous inhibitor, calpastatin. Calpastatin is an entirely unstructured protein; its
polypeptide is in a random coil formation when not bound to calpain [90]. Despite the
presence of only a single calpastatin gene in mammals, the use of at least four different
promoters and alternative splicing mechanisms allow the production of different
calpastatin polypeptides [88-90]. It appears that invertebrates do not possess the
calpastatin gene; any regulation of calpain activity by calpastatin is limited to vertebrates
[88]. No polypeptide sequenced thus far has homology to the calpastatin amino acid
sequence [90, 97]. Calpastatin is the only known inhibitor specific for the calpains [90],
Furthermore, calpastatin does not inhibit any other protease [88-91, 97].

Section 1.8: The db/db Mouse and Diabetic Cardiomyopathy

The db/db mouse was used to model Type 2 diabetes. The mouse has a point
mutation in the gene encoding the leptin-receptor (LEPR) [102-105]. Leptin is a hormone
that controls satiety and energy expenditure by acting on the hypothalamus through the
LEPR. Without the receptor, leptin does not exert its effects and the db/db mouse mimics
leptin deficiency and grows massively obese.
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As Aasum and colleagues noted, “the metabolic features of db/db mice are similar
to the pathogenesis of type 2 diabetes in humans.” Specifically, initial insulin resistance
is temporarily overcome by enhanced insulin secretion producing a state of
hyperinsulinemia [102]. Inevitably, elevated levels of insulin cannot maintain
normoglycaemia for long and in concert with dysfunctional changes in pancreatic p-cells,
insulin levels fall and severe hyperglycaemia ensues [102, 105]. db/db mice are also
reported to exhibit the characteristics of diabetic cardiomyopathy at 10-14 weeks of age
[54, 104, 106]. As in the human heart during diabetes, the db/db heart is associated with a
dependence on fatty acid oxidation for energy [107]. Derangements in cardiac
metabolism progresses with age as do contractile impairments including diastolic
dysfunction [106].

Section 1.9: Purpose of Study

Studies suggest that calpain activation may contribute to the progression o f heart
failure [91]. Calpains are implicated in ischaemia/reperfusion-induced cardiomyocyte
apoptosis and cardiac over-expression of calpain-1 was sufficient to cause heart failure in
transgenic mice [99]. In contrast, over-expression of calpastatin prevented troponin I
degradation and improved contractile function in rat hearts subjected to
ischaemia/reperfusion but also inhibited cardiac fibrosis in angiotensin-II induced mice as
shown by Manabe and colleagues [100]. Although an association between calpain and
cardiac dysfunction is clear, calpain over-activity in the context of diabetes has not been
examined nor, is there a type 2 murine model over-expressing the calpastatin gene.
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Section 1.10: Hypothesis

Overexpression of calpastatin will impede development of myocardial fibrosis caused
by elevations in calpain activity as a result of hyperglycaemia in a type 2 murine
model.

Section 1.11: Objectives of Thesis

1. Use a LEPR deficient murine model, db/db, to generate transgenic db/db mice
over-expressing the CAST gene (db/db-CAST) by crossing heterozygous db+/'
mice with homozygous transgenic mice over-expressing rabbit CAST.
2.

Assess heart tissues for indications of fibrosis. Determine if CAST over
expression imparted an anti-fibrotic benefit to db/db-CAST hearts.

3. Understand the action of calpain and CAST in fibroblast cells and specifically
their effect on fibroblast proliferation and differentiation to myofibroblasts.
4. Investigate whether CAST over-expression has any effect on impaired collagen
turnover and inflammatory responses in the diabetic heart.

CHAPTER 2: METHODS AND MATERIALS
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Section 2.1: Generation of the CAST Transgenic Model

Mice that are homozygous for the LEPR mutation are sterile [108], Therefore, to
generate the desired db/db-CAST model, heterozygous mice of the BKS strain were
crossed with homozygous transgenic mice over-expressing rabbit CAST of a C57BL/6
background. This cross can yield four possible genotypes: Lepr
CAST

-/-

db/-

CAST

+/-

, Lepr

db/-

-/+/-/-/, Lepr CAST
, Lepr CAST , each with a 25% probability of occurrence

(Figure 2.1). Mice with the first two genotypes, identified qualitatively by black fur
colour, are crossed to yield the second filial generation. In addition to the FI genotypes,
this cross can yield another four genotypes each with a 12.5% chance of occurrence:
-/-

+/-

Lepr CAST

-/-

, Lepr CAST

final cross, the db/db (Lepr

db/db

-/-

db/db

, Lepr

CAST

-/-

CAST

-/-

db/db

, Lepr

CAST

db/db

), db/db-CAST (Lepr

+/-

CAST

. From this

+/-

) and WT

7-/(Lepr CAST ) mice used in this study are produced (Figure 2.2).

Note: Leprdh dh' Leprdh", and Lepr denote homozygous (db/db) mice, heterozygous
(db+/-) mice and mice lacking the mutation, respectively.
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X
Lepr

CAST

Lepr

CAST-Tg

Figure 2.1: Schematic illustration representing the first filial cross
The db/db mouse is sterile. In order to produce db/db and db/db mice over-expressing the
CAST gene (db/db-CAST), heterozygous db+" mice will be crossed with db+" CAST
mice to yield four possible genotypes. Genotypes outlined in red were used in the second
filial cross.

21

L e p r db/- C A S T -/-

(25%)

L e p rdb/- C A S T +/~ (25%)
L e p r /_ C A S T + / ~ (12.5%)

Leprdb/-C A ST+/- x Leprdb/‘ CAST

Le p r c C A S T

[12,5%]

L e p rdb/db C A S J /- (12.5%)
Leprdb/db C A S T +/_ t«.5%)

Figure 2.2: Schematic illustration representing the second filial cross and offspring
CAST transgenic offspring heterozygous for the LEPR mutation were crossed with
heterozygous offspring without the CAST gene from the first generation. Four unique
genotypes are produced with a 12.5% chance of occurrence in addition to the two FI
genotypes, with are each produced with a 25% chance of occurrence. Genotypes outlined
in red were used. Outlined in green are the common names for each genotype as they will
be referred to in this study.
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Section 2.2: Genotyping
To determine transgenic CAST over-expression, l-2mm of tail was obtained from
three week old mice and digested overnight at 37°C in a solution of Proteinase K
(0.222mg/mL, Sigma-Aldrich, MO, USA) and 1 mL PBND [50 mM KC1, lOmM TrisHC1 (pH8.3), 2.5mM MgCl2-6H20, 0.1 mg/mL gelatin, 0.45% NP40, 0.45% Tween-20].
Proteinase K digests unwanted proteins, including nucleases, and keratin. Samples are
then heated first at 50°C for 1.5 hours then at 100°C for 5 minutes to inactivate
Proteinase K. Undigested material is pelleted after centrifugation (Eppendorf Centrifuge
5702, NY, USA) for 10 minutes at 10008xg and 2pL of lysate is used for PCR.
A pair of primers specific for rabbit CAST mRNA, not for the mouse CAST gene, were
used to amplify the transgenic rabbit CAST gene for 35 cycles (Px2 Thermal Cycler,
Thermo Electron Corporation, OH, USA):
Forward CAST primer: 5’ GTTGGCTTAGGCTGCTTTTCGT 3’
Reverse CAST primer: 5’ CCAGACTCCGTGACACCCCTT 3’

The PCR reaction was set as follows:
12.5 pL 2X PCR Mastermix (Fermentas),
0.4 pL (25pM) forward and reverse CAST primer
10.1 pL DEPC-treated water
2 pL lysates
25 pL Total Volume

Samples were run on a 2% agarose gel (containing ethidium bromide (EtBr)) at 80 volts
for 30 minutes and the signal was visualized under UV light.

23

Section 2.3: Calpain Activity
The calpain activity assay measures the fluorescence intensity of AMC (7-amino4-methylcoumarin) cleaved from the peptide substrate, N-succinyl-LLVY-AMC
(Cedarlane Laboratories, Burlington, Ontario). Heart tissue was placed in 250pL of lysis
buffer [1M HEPES (pH 7.4), 50 mM CHAPS (5 mL), 1M 0.1% DTT (0.5mL), 5mM
EDTA (20pL)] homogenized and centrifuged at 22680xg for 15 minutes. Supernatant
was removed and protein concentration was measured using a DC Protein Kit (Bio-Rad)
and the concentration of all samples was equalized by adding appropriate amounts of
reaction buffer (63 mM imidazole-HCl, pH 7.3, 10 mM P-mercaptoethanol, 1 mM
EDTA, and 10 mM EGTA). The samples were incubated for two hours at 37 °C in either
reaction buffer with or without calcium chloride (5 pM or 5 mM) or reaction buffer with
or without calcium chloride (5 pM or 5 mM) in addition to 5 pM of calpain inhibitor,
PD 150606 (Li et al., 2009). The fluorescence intensity of cleaved AMC was quantified
with a multilabel reader (excitation, 360 nm; emission, 460 nm) (Victor 1420 Multilabel
Counter, PerkinElmer, MA, USA) and calpain activity was determined as the difference
between calcium-dependent and calcium-independent fluorescence. (Li et al., 2009).

24

Section 2.4: Insulin measurement
Blood samples were collected and centrifuged at 907xg for 15 minutes at 4°C. Plasma
samples were transferred and stored at -85 °C until use. An ELISA-based rat/mouse
insulin kit was purchased from Millipore (St. Charles, MO) and used to conduct insulin
measurements. Each well of the microtiter assay plate provided was washed three times
with 300pL of wash buffer (50 mM Tris Buffered Saline with Tween-20) that was diluted
10 fold using distilled water. Diluted wash buffer was decanted after each wash.
To designated standard and control wells: lOpL rat insulin standards were added in the
following order of concentration: 0.2 ng/mL, 0.5 ng/mL, 1 ng/mL, 2 ng/mL, 5ng/mL and
10 ng/mL. Additionally, 10 pL matrix solution (charcoal stripped pooled mouse serum)
was also added.
To sample wells: 10 pL of the plasma samples were added.
Subsequent additions to both control and sample wells included:
•

10 pL assay buffer (0.05 M phosphosaline, pH 7.4, containing 0.025 M EDTA,
0.08% sodium azide, and 1% BSA)

•

80 pL detection antibody (pre-titered biotinylated anti-insulin antibody)

The plate was then sealed and incubated for two hours at room temperature after which
the solutions were decanted from the plate and each well was again washed three times
with diluted wash buffer, 300 pL per wash. Subsequently, 100 pL of enzyme solution
(pre-titered streptavidin-horseradish peroxidase conjugate in buffer) was added to each
well and the plate was sealed and incubated for 30 minutes. The enzyme solution was

25

emptied out and each well was washed 6 times with 300pL of the diluted wash buffer per
wash. Then 100 pL of substrate solution (3, 3’, 5, 5’-tetramethylbenzidine in buffer) was
added to each well, the plate was covered until a blue colour formed in wells at which
point 100 pL o f the stop solution (0.3 M HC1) was added. Absorbance was read at 450
nm and 590 nm in a microplate reader (Model 680 Microplate Reader, Bio-Rad,
Hercules, CA, USA) and insulin was measured as the difference between the two.

Section 2.5: RNA Isolation and cDNA synthesis
Heart tissue was homogenized in 1 mL TRIzol reagent (Invitrogen, Burlington, Ontario)
and chloroform (EMD Chemicals Inc., Gibbs Town, NJ, USA) was used to separate
aqueous and organic phases before centrifugation at 14490xg for 15 minutes. Isopropyl
alcohol (EMD Chemicals Inc., Gibbs Town, NJ, USA) was added to the aqueous phase
then decanted to precipitate the RNA. Reagent alcohol (VWR International, Westchester,
PA, USA) was added then decanted and the pellet was dissolved in DEPC-treated water.
UV absorbance at 260 nm was used to measure total RNA and at 260:280 nm to measure
and standardize sample purity using a spectrophotometer. To synthesize cDNA, 1 pL of
oligo (dT) (0.5 pg/mL, Sigma Genosys, Oakville, Ontario) was added to 3 pL total RNA
(3 pg), and denatured at 65°C for 10 minutes. A mixture of dNTP (Sigma Aldrich, MO,
USA), reverse transcriptase (Sigma Aldrich, MO, USA) and reverse transcription buffer
(Sigma Aldrich, MO, USA) were added to the samples followed by a 50 minute
incubation at 37°C. The reaction was stopped by heating the sample at 65°C for 5
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minutes. DEPC-treated water was added to 20pL of cDNA to bring the total volume to
180pL. cDNA samples were stored at -20°C.

Section 2.6: Qualitative Real Time RT-PCR
The reaction mixture was as follows:
10 pL

2X SYBR Green Taq MasterMix (Fermentas, CA, USA)

5 pL

DEPC-treated water

0.5 pL Forward primer (50 pmol/L)
0.5 pL Reverse primer (50 pmol/L)
4 pL

cDNA

20 pL Total volume

GAPDH was the housekeeping gene used to normalize the data. Real-time RT-PCR was
performed in the MiniOpticon Thermocycler (Bio-Rad Laboratories, Hercules, CA,
USA). The primers (Sigma GenoSys, Oakville, ON, Canada) and temperature profiles
used are found in Table 2.1.
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Table 2.1 Primer Sequences and Temperature Profiles for Real Time RT-PCR
Primer

Sequence (5’-**3’)
Phase

TGF-ßl

(+) TTGCTTCAGCTCCACAGAGA
(-) TGGTTGTAGAGGGCAAGGAC

Osteopontin

(+) GACGACGATGATGACGATGA
(-) CCTCAGTCCATAAGCCAAGC

a-SMA

(+) GTCCCAGACATCAGGGAGTAA
(-) TCGGATACTTCAGCGTCAGGA

CAST

(+) GTTGGCTTAGGCTGCTTTTCG
(-) CCAGACTCCGTGACACCCCTT

Collagen 1

(+)ACGGCTGCACGAGTCACAC
(-) GGCAGGCGGGAGGTCTT

Collagen III

(+) GTTCTAGAGGATGGCTGTACT
(-) TTGCCTTGCGTGTTTGATATT

TIMPl

(+) ATTCAAGGCTGTGGGAAATG
(-) CTCAGAGTACGCCAGGGAAC

TIMP2

(+) CACAGACTTCAGCGAATGGA
(-) CTTGGGAAGCTTGAGAGTGG

TIMP3

(+) AGCTGGCAAAGGCTTAAACA
(-) CAAGCTTCCAGCCAAACTTC

PCR Conditions
Temperature- Time

Initial Dénaturation
Dénaturation
Annealing
Extension

95°C- 10 minutes
95°C- 15 seconds
60°C- 30 seconds
72°- 30 seconds
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Section 2.7: Collagen Staining
Tissue was fixed in 10% formalin and then embedded in paraffin and 7 pm sections were
cut and transferred to slides which were de-paraffinized in two changes of xylene and
hydrated in two changes of 100% ethanol for 10 minutes, 95% ethanol for 3 minutes,
85% ethanol for 3 minutes and finally in 75% ethanol for 2 minutes. Slides were washed
and placed in Picrosirius red solution for one hour then subsequently dehydrated in
ethanol and cleared in xylene before being mounted in a resinous medium. Picrosirius red
solution was comprised of 0.5g Sirius red (Cat#365548, Sigma-Aldrich, MO, USA) and
500mL picric acid solution (Cat# P6744-1GA, Sigma-Aldrich, MO, USA). Sigma-Scan
Pro software was used to quantify levels of collagen deposition. A total of 10 fields from
each slide were analyzed with a 20X objective lens.

Section 2.8: Echocardiography
Mice were anaesthetized using a ketamine/xylazine (100/10 mg per kg body weight)
combination injected intraperitoneally. Echocardiographic measurements were conducted
using tissue Doppler imaging at Robarts Research Institute (London, Ontario). M-mode
images were obtained and analyzed [106].

Section 2.9: Cardiac Fibroblast Cell Culture
Three month old mice were injected with 40pL heparin in a 1:40 dilution in distilled
water. Thirty-minutes later, heart tissue was removed from mice, minced and washed
three times with IX D-Hanks solution then incubated at 37°C with an enzyme mixture
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prepared from 0.01 g collagenase type 2 (Worthington Biochemical Corp., Lakewood, NJ)
and 0.006 g dispase (Roche Diagnostics, Mannheim, Germany) in 10 mL D-Hanks
solution (Sigma-Aldrich, MO, USA) for forty-five minutes to digest tissue and liberate
fibroblast cells. The enzyme/sample mixture was centrifuged for 5 min at 8xg (Eppendorf
Centrifuge 5180R, NY, USA) after which the supernatant was discarded and the pelleted
fibroblast cells were suspended in 3mL Dulbecco’s modified eagle medium (DMEM)
(HyClone Laboratories, ThermoFisher Scientific, Utah, USA) supplemented with 10%
FBS (Gibco, Invitrogen, Grand Island, NY, USA) and 100 pg/ml penicillinstreptomyocin (Invitrogen, Burlington, ON, Canada) and seeded in Falcon plates. After
two hours of incubation at 37°C, the medium was replaced with 3mL of fresh medium.
Section 2.10: Cardiac Fibroblast Digestion and High Glucose Stimulation
Cardiac fibroblast cells were cultured for three days at which point the culture medium
was removed and the cells were suspended in 2 mL of trypsin for 2 minutes in order to
re-suspend cells that have adhered to the plate surfaces. The solution was then
centrifuged for 5min at 8xg. The supernatant was discarded and the pellet was suspended
in 2mL of culture medium. An equal number of cells was measured into the appropriate
wells in a 96-well plate and incubated at 37°C. The next day, culture media is replaced
with 1OOpL o f either normal or high glucose media and incubated for one additional day
at 37°C. Normal glucose (5.5 mM) media is comprised of 50mL DMEM supplemented
with 2% FBS and 100 pg/ml penicillin-streptomyocin. High glucose media, 33 mM, is
prepared the same way except for the addition of 0.243g of D-glucose (dextrose)
(Invitrogen, Burlington, ON, Canada).

30

Section 2.11: MTT Proliferation Assay
After high glucose stimulation, 15pL of MTT solution is added to all wells. MTT
solution is prepared by mixing 5mg of MTT (Thiazolyl blue: 98% TLC, Sigma) and lmL
of distilled water. The solution is stored at -20°C. Three to four hours after incubation
with MTT solution at 37°C, the wells are decanted and 150pL dimethyl sulfoxide
(DMSO) is added to each well. A multilabel reader is used to measure absorbance
(540nm). Proliferation is assessed using the averaged ratios of high to normal glucose for
each group.

Section 2.12: MMP activity measurement
Fibroblasts were cultured and stimulated as described in Section 2.9 and 2.10. The
supernatant of cell culture media was collected, centrifuged at lOOOrpm for 15 minutes
and stored at -70°C until use. The fluorimetric SensoLyte® 390 Generic MMP Assay Kit
(Anaspec, CA, Cat #72202) was used to measure MMP activity. As per the
manufacturer’s instructions the samples were incubated with 1 mM (APMA) for two
hours at 37°C. MMP substrate was diluted 1:100 in assay buffer and 50pL were added to
samples and control wells. Additional assay buffer was added in order to bring the total
volume to 50pL in control wells only. The samples were incubated at room temperature
for 30 minutes and fluorescence intensity was measured at Ex/Em=330 nm/390 nm.
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Section 2.13: Toluidine Blue Staining for Mast Cells
Tissue was fixed in 10 % formalin and embedded in paraffin. Sections of 5 micron
thickness were transferred to slides which were de-paraffinized in two changes o f xylene
and hydrated in two changes o f 100% ethanol for 10 minutes, 95% ethanol for 3 minutes,
85% ethanol for 3 minutes and finally in 75% ethanol for 2 minutes before being washed
and placed in acidic toluidine blue solution. After three minutes, the slides were
subsequently dehydrated in ethanol and cleared in xylene before being mounted in a
resinous medium. Mast cell numbers were visually quantified using a light microscope at
20x magnification.

Section 2.14: Statistical Analysis
The Student’s t-test was used to compare differences between two treatment groups.
ANOVA followed by the Tukey test was performed to examine statistical differences
across multiple groups. A value of p< 0.05 was considered statistically significant and
data are given as mean ± SD.

CHAPTER 3: RESULTS
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Section A: Characterization of the mouse model

3.1 Generation of CAST Transgenic Mice
Mice homozygous for the LEPR mutation are sterile [108]. To produce the
desired db/db-CAST model, homozygous transgenic mice over-expressing rabbit CAST
are bred with mice heterozygous for the LEPR mutation in two successive crosses.
Homozygous (db/db) and heterozygous (db+/-) offspring are separated on account of
body size. As demonstrated by Figure 3.1 A, a db/db mouse is twice as large as its
heterozygous littermate. Among the db/db group, mice are screened for CAST
overexpression by genotyping tissue obtained from mice tails upon weaning at three
weeks of age (Figure 3. IB).
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Figure 3.1: Characterization of WT, db/db and db/db-CAST mice
A) The picture depicts the qualitative differences between the three types of mice
used in this study. Wildtype mice are grey (1). Heterozygous mice are black (2)
and lean, db/db, and db/db-CAST mice are black and obese (3).
B) Genotyping. Tail samples were used to detect the presence of the rabbit CAST
gene by PCR. A representative agarose gel for rabbit CAST gene from 9 different
mice shows that lanes #1, 2, 5, 8 and 9 are positive and lane #3, 4, 6 and 7 are
negative.
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3.2: Insulin Measurement and General Parameters

The db/db mouse is a type 2 diabetic model that exhibits many consequences of
diabetes including hyperglycaemia, hyperinsulinaemia and hyperlipidaemia [102], At
three months of age all db/db and db/db-CAST mice had high blood glucose defined as a
blood glucose level exceeding 33mmol/L and was measured using a OneTouch glucose
monitor. Body weight measurements do not show any significant difference in weight
between db/db and db/db-CAST mice. Nor is there any significant difference in the
weight of the heart (Table 3.1). To ensure differences in plasma insulin levels are not
contributing to the results, insulin measurements were taken and found to be similar
between db/db and db/db CAST groups (Figure 3.2).

36

Table 3.1: Weight and Blood Glucose
Body Weight (g)

Heart Weight (g)

Blood Glucose

WT

35.06 ± 1.03

0.14 ±0.03

Normal

db/db

68.52 ±3.55

0.17 ±0.01

High (>33mmol)

db/db-CAST

67.81 ±3.91

0.16 ±0.01

High (>33mmol)

Insulin levels (Absolute Units)
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db/db

db/db-CAST

Figure 3.2: Insulin levels are similar in db/db and db/db CAST mice.
Measurements of insulin from both db/db and db/db CAST mice did not show any
difference. Data are mean ± SD, n=5.
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3.3: Calpain activity is elevated in diabetic mice

An activity assay measuring calpain activity in heart tissues from WT and db/db
mice showed a significant increase in calpain activity in db/db mice compared to control
mice (Figure 3.3). This ensured the db/db mouse model would be appropriate in which to
test our hypothesis regarding calpain hyperactivity.
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Figure 3.3: Diabetic hearts have elevated calpain activity.
Calpain activity assays confirm increased calpain activity in diabetic myocardia. Data are
mean ± SD, n=5. *P <0.05 vs. WT.
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Section B: Myocardial Remodelling

3.4: Collagen Deposition

Myocardial fibrosis is a typical feature of cardiomyopathy in the diabetic heart
and is characterized by excessive production and accumulation of extracellular collagen
[9, 10, 19, 22, 51]. Tissue was formalin-fixed and embedded in paraffin. Sections of 7
micron thickness were de-paraffinized in xylene and rehydrated through graded alcohols
then placed in Picrosirius red solution for one hour before mounting in a resinous
medium. Collagen areas were manually traced using SigmaScan Pro software. The
histological analysis revealed increased collagen deposition in db/db mice (0.035 ± 0.003
area units) compared with the control group (0.02 ± 0.004 area units). Heart sections of
db/db-CAST mice had significantly reduced collagen content (0.022 ±0.004 area units)
(Figure 3.4).
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WT

db/db

db/db CAST

*

Control

db/db

db/db-CAST

Figure 3.4: Collagen deposition in the diabetic heart is reduced by CAST over
expression
A) Representative micro-pictures for collagen staining from one out of five hearts in each
group are presented. Collagen is highlighted by red staining (arrow, original
magnification x20). B) Quantification of collagen content. The amount of collagen was
assessed manually in 10 fields per tissue section and shown as the ratio between collagen
quantified in the field and total area of the field. Data are mean ± SD, n=5/group.
*p<0.05.
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3.5: Gene Expression of Collagens I & III

In order to assess the impact of calpain hyperactivity on levels of collagens I and
III, the major collagen types in the myocardium [56], heart tissues were analyzed using
real time RT-PCR. Collagens I and III, expressed as a ratio of collagen I or III to the
house-keeping gene, GAPDH, were up-regulated in db/db hearts but over-expression of
CAST lowered their levels by 53% and 64%, respectively (Figure 3.5).
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Figure 3.5: CAST downregulates collagen I and III mRNA expression.
The mRNA levels of collagen I (A) and collagen III (B) in the myocardium were
quantified by real time RT-PCR. Data are expressed as the ratio of Collagen I or III to
GAPDH. Data are mean ± SD, n=l 1-13/group, *p<0.05.
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3.6: Collagen Ratios

The ratio of collagen I to collagen III at the mRNA level has also been reported as
an indicator of fibrosis in the myocardium [109, 110]. In this study, there was a clear shift
in the collagen ratio from db/db mice to db/db-CAST mice whose collagen ratio was
equivalent to the control (Figure 3.6). Taken together, the results suggest calpain
inhibition is important in reducing increases in absolute amounts of collagens I and III
induced by hyperglycaemia.
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Figure 3.6: Collagen Ratios in the diabetic heart
Ratio of collagen I to collagen III at the mRNA level show that CAST maintains the
necessary equilibrium between the two collagen types. Data are mean ± SD, n=l 113/group, *p<0.05.
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3.7: Left Ventricular (LV) Wall Thickness
Structural changes at the microscopic level can translate to macroscopic
alterations of the entire organ [51]. Echocardiography was used to assess left ventricular
wall thickness. Although not statistically significant, the results show greater wall
thickness in db/db diabetic mice compared to both control and db/db-CAST mice (Figure
3.7).

(arbitrary units)

LV Posterior W all Thickness
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Figure 3.7: Diabetic hearts exhibit increased left ventricular wall thickness.
The LV wall thickness was assessed at the papillary level by echocardiography. Data are
mean ± SD, n=6/group.
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Section C: Fibroblast Proliferation and Differentiation

3.8: Hyperglycaemia induces fibroblast proliferation
Fibroblasts are believed to be key mediators of fibrosis in the injured or failing
heart [63, 64, 111]. In the diabetic, cardiac fibroblasts are exposed to sustained
hyperglycaemia [67]. To understand the effect this would have on the fibroblast
population in the myocardium, cardiac fibroblast cells from wildtype mice were cultured
and subjected to either normal (5.5 mM) or high glucose treatments (30 mM). The use of
cells isolated from wildtype mice ensures the results will not be complicated by the
effects o f pre-existing hyperglycaemia. Exposure to high glucose for 24 hours was
sufficient to cause an increase in fibroblast proliferation. However, under the same
hyperglycaemic conditions, proliferation was reduced by pharmacological calpain
inhibition (Figure 3.8A). Cardiac fibroblasts from db/db mice were also cultured.
Compared to the control group, the db/db group had higher proliferation regardless of
glucose exposure, in vitro (Figure 3.8B). Increases in fibroblast proliferation became
more pronounced upon 24 hour high glucose treatment, once again confirming
hyperglycaemic conditions are sufficient to induce a proliferative response in cardiac
fibroblast cells. These results suggest that fibroblast cells are more prone to proliferation
in db/db mice whether in normal or high glucose medium implying greater fibroblast
activity in the diabetic myocardium.
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WT

db/db

Figure 3.8: Proliferation of cardiac fibroblast cells from WT and db/db hearts.
Cardiac fibroblast cells were isolated from WT and db/db mouse hearts. Twenty-four
hours after passaging, fibroblast cells were subjected to normal or high glucose for one
day. An MTT assay was performed to assess cell proliferation. A) High glucose increased
fibroblast proliferation which was reversed by calpain inhibitor-III (10 pM). Data are
mean ± SD, n=4 *p<0.05. B) db/db cardiac fibroblasts were more proliferative than WT
cardiac fibroblasts regardless of glucose treatment. Proliferation is expressed using
arbitrary units. Data are mean ± SD, n=4.
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3.9: Fibroblast proliferation is limited by CAST over-expression
In order to elucidate the role calpain over-activity may play in provoking
fibroblast proliferation, cardiac fibroblast cells from db/db and db/db-CAST mice were
both cultured and incubated with normal and high glucose for one day. Proliferation was
greater in db/db cells but significantly reduced by CAST over-expression in both
treatments (Figure 3.9). Fibroblasts are the primary effectors of fibrosis and evidently,
one likely target of calpain over-activity in hyperglycaemia.
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Figure 3.9: CAST over-expression limits fibroblast cell proliferation.
MTT assays of cultured cardiac fibroblast cells from db/db and db/db CAST mice shows
CAST over-expression impedes proliferation of fibroblasts in diabetic murine hearts.
Proliferation is calculated as a ratio of average high glucose to average normal glucose
wells and expressed using arbitrary units. Data are mean ± SD, n=4, *p<0.05.
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3.10: TGF-pl promotes fibroblast differentiation in db/db hearts

TGF-pi is a known fibrogenic cytokine [58, 65]. To determine if TGF-pi is
differentially expressed among the three experimental groups, heart tissues from WT,
db/db and db/db CAST mice were subjected to real time RT-PCR. The mRNA levels of
TGF-pi were increased in db/db mice. However, the increase was reduced to control
levels by over-expression of CAST (Figure 3.10).
TGF-pi is known to induce differentiation of fibroblasts to myofibroblasts which
have a higher capacity for collagen production [69, 72, 112]. During their formation,
myofibroblasts irreversibly acquire proteins such as smooth muscle actin-alpha (a-SMA)
making it a key indicator of fibroblast differentiation [113-115], Although the results did
not reach significance, real time RT-PCR performed on heart tissue from the three groups
indicate that a-SMA expression is increased in diabetic db/db hearts but not in db/db
CAST hearts (Figure 3.11 A).
Another protein indicative of fibroblast differentiation is osteopontin (OPN) [1 lb120]. OPN is involved in intracellular signals required to induce the proliferation and
migration of Myofibroblasts [116, 120, 121]. As expected, OPN levels were highest in
diabetic hearts but CAST reduced OPN expression (Figure 3.1 IB). Taken together the
results suggest calpain inhibition prevents fibroblast differentiation.
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Figure 3.10: TGF-pi mRNA expression is up-regulated in the diabetic heart
The mRNA levels of TGF-pi in the diabetic heart were determined by real-time RTPCR. Up-regulation of TGF-pi is seen in diabetic hearts however, CAST over
expression leads to reduced TGF-pi levels. TGF-pi mRNA levels are expressed relative
to GAPDH. Data are mean ± SD, n=3-7, *p<0.05.
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Figure 3.11: CAST inhibits fibroblast differentiation as indicated bya-SMA and
OPN expression.
The mRNA levels of a-SMA (A) and OPN (B) in the heart were determined by real-time
RT-PCR. mRNA expression is shown as a ratio of a-SMA or OPN to GAPDH. Data are
mean ± SD, n= 8-11, *p<0.05.
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Section D: Collagen Turnover and Inflammation

3.11: CAST reverses MMP and TIMP imbalance
In order to determine if impaired collagen turnover may be a perpetuating factor
in the development of fibrosis in the myocardium, MMP activity assays were performed
on cultured cardiac fibroblast cells. As shown in Figure 3.12, MMP activity was
consistently lower in the high glucose treated cells that inhibited cal pain either
transgenically or pharmacologically using calpain-inhibitor III than in cells that were
exposed only to a hyperglycaemic medium suggesting calpain and hyperglycaemia may
work synergistically to increase MMP activity. The mRNA levels of TIMP 1 and TIMP2
were measured in heart tissues collected from the three groups. As shown in Figure 3.13,
the levels of both TIMP1 and TIMP2 mRNA were elevated in the diabetic group.
However, CAST over-expression reduced TIMP1 and TIMP2 mRNA expression in the
diabetic heart.
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Figure 3.12: High glucose mediates increased MMP activity in cultured cardiac
fibroblast cells.
The activity level of MMPs were decreased in fibroblast cells cultured from the
myocardium of transgenic mice over-expressing CAST and wildtype mice whose cells
were treated with calpain-inhibitor III. Data is mean ± SD, n=3, *p<0.05.
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Figure 3.13: TIMP expression in diabetic db/db hearts
The mRNA levels of TIMP 1 and TIMP2 were quantified by real-time RT-PCR in the
hearts of diabetic mice. Their mRNA expression is shown relative to GAPDH. Data is
mean ± SD, n=3-6, *p<0.05.
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3.12: Mast cells in the diabetic heart

Mast cell infiltration is correlated with fibrosis in numerous organ systems [122,
123]. It has been suggested that mast cells may potentiate fibroblast proliferation and may
thus promote the progression to myocardial fibrosis in diabetes [123-126] . In this study,
heart sections of 5 micron thickness were stained in toluidine blue and mast cell numbers
were visually quantified at 20x magnification. The db/db mice had greater mast cell
density than wildtype mice. However, as shown in Figure 3.14, CAST over-expression
prevented mast cell infiltration in the diabetic heart.

59

Figure 3.14 Mast cell hyperplasia is minimized by CAST over-expression.
Heart sections were stained using toluidine blue. A) A representative micro-picture for
mast cell staining (arrow pointing to mast cells, purple-red colour signal) from 3-6 heart
tissues in each group B) Mast cells were visually quantified at 20x magnification and
expressed as the number of mast cells in each section. Data is mean ± SD, n=3-6,
*p<0.05.

CHAPTER 4: DISCUSSION
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Elevated calpain activity is a feature of the failing myocardium [91, 96, 101] .
However, it has been relatively understudied as a potential mechanism underlying the
maladaptive changes seen in the diabetic heart. This study demonstrated first that a
successful animal model of type II diabetes over-expressing calpastatin could be
generated in order to study the influence o f calpain in diabetic heart failure. Second,
collagen deposition is limited by calpastatin over-expression and may consequently
hinder progression to heart dysfunction and eventual failure. Lastly, the fibroblast cell is
one of the targets of calpain over-activity as calpastatin over-expression clearly prevented
fibroblast activity including proliferation (Figure 4.1).
The db/db mouse exhibits the characteristic features of type 2 diabetes early in its
life cycle [102, 103]. They become identifiably obese around three to four weeks of age.
Elevation of blood glucose begins at four to eight weeks [102]. Initially, hyperglycaemia
leads to insulin resistance and hyperinsulinemia [102, 103, 105]. Lipolysis and enhanced
lipoprotein synthesis in the liver results in a greater supply of free fatty acids which
eventually hijack cardiac metabolism [24-26]. Cardiac dysfunction appears soon after and
becomes progressively more pronounced with age [106], The db/db and db/db-CAST
mice had the same metabolic features. Both grew obese within three weeks and were
hyperglycaemic at the time of sacrifice. There was no difference in body weight and heart
weight between the two and no modified behaviour in db/db-CAST mice was observed.
Previous studies in our lab and others have shown calpastatin over-expression does not
interfere with calpain activity in normal physiologic conditions [90, 95, 97], Thus, the
systemic effect of calpastatin-over-expression on metabolism, if any, may be negligible
in db/db mice.
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Figure 4.1: Schematic diagram representing the different players influenced by
calpain inhibition.
This study showed calpain inhibition reduced the amount of absolute collagen deposited
in the ECM. A mechanistic study points to the involvement of mast cells, TGF-(3 in
stimulating fibroblast activity. Modifications in collagen turnover may also be involved.

In this study, we demonstrated that inhibition of calpain activity via calpastatin
over-expression was successfully able to inhibit the increase in collagen deposition seen
in db/db hearts. Collagen is vital to the maintenance of cardiac architecture. Yet, slight
increases in collagen content can translate into mechanical impairments [57, 127]. An
echocardiograph also showed the thickness of the left ventricular wall to be decreased in
db/db-CAST mice suggesting microscopic improvements were sufficient enough to cause
structural changes in the whole organ. Furthermore, the decrease in collagen
accumulation in the treatment group resulted in a collagen ratio equivalent to the one in
the wildtype control group. Collagen I is characterized by tensile strength whereas
collagen III has greater elastic potential [56], Thus, ratios between collagen types are
significant as they may have a substantial impact on the diastolic and systolic function of
the heart [110, 127]. Clearly as calpain over-activity is restrained, the amount of total
collagen accumulation in the hyperglycaemic heart is diminished and the relative
amounts of collagens I and III are brought back to homeostatic levels.
Having established a correlation between calpain activity and collagen content in
the myocardium, we isolated and cultured cardiac fibroblast cells from all three groups of
mice and subjected each set to high and normal glucose treatments. Many biological
mechanisms thought to contribute to or cause myocardial fibrosis point in some way to
the involvement o f the fibroblast cell [63, 65, 74, 128], The fibroblast is hard to ignore; it
is the cell type largely responsible for maintaining the extracellular matrix [56, 57]. The
study aimed to identify fibroblasts as targets of calpain hyperactivity and examine the
mechanisms that relate calpain to fibroblast stimulation. Results showed a significant
increase in proliferation under the influence of hyperglycaemia, not surprising since they

are a significant cell population in organs commonly affected by diabetes including the
kidney and liver [63, 129], The novel finding proved to be the effect of calpastatin on
fibroblast proliferation. In comparison, cultured fibroblast cells from db/db-CAST mice
had consistently reduced levels of fibroblast proliferation than db/db mice. Furthermore,
when wildtype fibroblast cultures were subjected to high glucose in addition to a
pharmacological calpain inhibitor, they mirrored the results from db/db-CAST cultures
with a drop in proliferation compared to wildtype fibroblast cells that had been treated
only with high glucose. Because the calpain inhibitor used is not entirely specific for
calpain but also a number of other proteases, the results have their limitations. However,
combined, the effects of calpastatin over-expression and pharmacological calpain
inhibition make a compelling case for an association between fibroblast activation and
calpain activity.
TGF-pi has gained notoriety as a potent fibrogenic cytokine [65]. Upon tissue
injury, it can spur fibroblasts into action by stimulating the release of ECM proteins,
particularly collagen, and initiate wound healing and repair [58]. But further research
into the mechanisms behind fibrosis has highlighted its ability to promote excess and
secretion of collagen from fibroblasts [58, 65, 71, 72]. Among its pro-fibrotic abilities,
TGF-fS can induce the differentiation of fibroblasts to specialized contractile fibroblasts
called myofibroblasts [70, 72, 74], Over the course of their development, myofibroblasts
irreversibly acquire proteins, one of which is a-SMA, a well-accepted marker of
myofibroblast differentiation [113-115]. Another marker is OPN which coordinates
intercellular signals required to integrate myofibroblast proliferation, migration and ECM
deposition [117-120, 130-133]. OPN may require its secretion by myofibroblasts, and
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may promote differentiation [120, 133]. This study showed an up-regulation of TGF-p in
db/db mice as expected but in the calpastatin over-expression group the expression of
TGF-P was reduced. The expression of a-SMA and OPN showed the same trend
suggesting calpastatin prevented TGF-P stimulation and consequently prevents the
cytokine from stimulating fibroblast differentiation.
Being a key pro-inflammatory cytokine, TGF-P 1 can induce mast cell chemotaxis
[82, 134-136]. Mast cell infiltration is a common observation in tissue repair processes
regardless of the underlying diagnosis [137, 138]. Hearts from db/db mice showed
increased mast cell density in tissue sections than db/db CAST mice indicating the
involvement of calpain at some point in the inflammatory process. Previous studies, in
vitro, have showed that mast cells may enhance fibroblast viability when co-cultured
[137]. Interestingly, mast cells are a major source of TGF-pI and TNF-a for example, and
may stimulate fibroblast activity through these secretion products [137, 139]. Yet, the
exact relationship between mast cells and fibroblasts is still under examination.
Collagen synthesis is driven by fibrogenic factors, especially TGF-P, acting at the
transcriptional level. However, collagen degradation is regulated by the MMP
superfamily and impaired collagen turnover is a perpetuating factor in the development of
myocardial fibrosis [76-80]. This study shows that stimulation by calpain is not limited
only to the fibroblast, whether directly or indirectly through fibrogenic factors, but also to
the remodelling machinery in the ECM. MMP levels were increased in the fibroblast cells
of wildtype mice exposed to high glucose but not in the fibroblast cells of calpastatin
transgenic mice. Wildtype fibroblast cells treated with calpain inhibitor III did not
demonstrate an increase in MMP activity either thus highlighting the multidimensional

role of calpain in promoting the fibrotic phenotype. MMP production is regulated by
TIMPs. In agreement with the results of our study, elevations in TIMP expression are a
confirmed occurrence in diabetes [75, 140], Yet, we showed that with calpastatin over
expression levels of TIMPs were reduced (TIMP1) or returned to normal levels (TIMP2).
This study has shown calpain inhibition as an effective means of decreasing total
collagen accumulation in the diabetic heart. Experiments designed to understand the
mechanisms responsible for the ability o f calpain to promote fibrosis under
hyperglycaemic conditions have pointed to over-activation of fibroblasts and the
signalling pathways affecting fibroblast function. Derangements in MMP activity and
stimulation of the immune response may also play a concerted role in the development of
fibrosis in diabetic cardiomyopathy [134],
There are limitations in using mice to model human heart disease, a major one
being the much higher heart rate and basal systolic contraction levels in the murine heart
and the difference in resident cell populations in the myocardium across species [102].
But although the cardiac phenotype present in the mouse cannot be extrapolated to the
human diabetic in its entirety, the fact that rodents are not susceptible to atherosclerosis is
a major boon in their use because a diabetic model without any complicating coronary
artery disease provides a suitable backdrop to examine the evidence of a cardiomyopathy
unique to diabetics [102]].

CHAPTER 5: FUTURE STUDIES
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Collagen deposition was consistently decreased in db/db CAST mice.
Undoubtedly, this should restore some measure of function to the myocardium. The most
obvious next step should consist of a functional study using echocardiography or
perfusion techniques to determine if the myocardia from mice over-expressing calpastatin
have improved mechanical properties compared to db/db mice.
In the course of cellular metabolism, mitochondria generate numerous reactive
oxygen species such as superoxide; highly reactive and capable of damaging nucleic
acids and protein structure [44, 141-144], The cell has numerous antioxidant defense
mechanisms however, should ROS production exceed ROS elimination, oxidative stress,
another hallmark event in the course of diabetic cardiomyopathy, will ensue [145-149]. A
transcription factor, NF- kB, is implicated in promoting fibrosis by enhancing ROS
production [81, 150]. NF-kB is also an important mediator of the inflammatory response
and activates numerous cytokines including TGF-[3 and TNF-a and participates in the
recruitment of immune cells, including mast cells [151, 152], Its activation is initiated by
the degradation of its inhibitor, IkB which can be accomplished by calpain [153]. Thus, it
could prove worthwhile to measure NF-kB activity by extracting nuclei from all three
groups o f mice to determine if NF-kB activity is down-regulated by calpastatin. Further,
in previous studies in our lab we demonstrated that hyperglycaemia is associated with
increased activity of calpain in mitochondria in a type 1 diabetes model. The same
approach can be used to determine if increased mitochondrial calpain plays a causal role
in raising whole cell ROS production in a type 2 model.
Arguably, the greatest leap in understanding the calpain/calpastatin system would
come with a precise account of the biological roles calpain performs and upon which
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substrates it acts. Unfortunately, this task is complicated for a number of reasons. Calpain
is distributed throughout the cytosol and as result has no association with a specific
organelle that would hint to its purpose [88, 89]. Nor is the amino acid sequence o f any
calpain isoform indicative of its substrate because calpain functions conformationally
[88, 89]. The protease is also difficult to purify in an undegraded form [75]. Another
significant obstacle in determining calpain function experimentally is that the calcium
requirement for calpain activation in experiments is much higher than physiological
concentrations found in living cells rendering laboratory studies difficult [88, 89].
However, continued research on the calpain molecule itself and indirect studies on the
consequences of altered calpain activity in various pathologies, such as this study on
diabetic cardiomyopathy, should provide a clearer picture of this protease’s elusive
properties.

CHAPTER 6: SIGNIFICANCE OF STUDY
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Cases of diabetes continue to rise despite awareness initiatives and extensive
research into its cause and treatment [1-4]. Rising obesity rates, sedentary lifestyles and
an aging population are all contributing factors. Though the economic cost is enormous,
the cost to patients is greater [4]. The ultimate goal is to find ways in which diabetes can
be cured. However, this goal is complicated by the introduction of numerous related
illnesses and pathologies especially diabetic cardiomyopathy[2-4]. This study
demonstrated, for the first time, that hyperglycaemia-induced fibrosis in the myocardium
can be reversed or inhibited by calpain inhibition. Yet, this only scratches the surface as
calpain activation has been shown to have key importance in the promotion and
development of the fibrotic phenotype not only in the diabetic but all patients of heart
disease [95, 97, 99, 101, 154]. Additionally, understanding the calpain-calpastatin system
may lead to a deeper understanding of cardiovascular biology in general, both in normal
and diseased states.
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